{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:12:22Z","timestamp":1792271542932,"version":"4.4.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81571969"],"award-info":[{"award-number":["81571969"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81673045"],"award-info":[{"award-number":["81673045"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12016-019-08747-8","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T12:02:40Z","timestamp":1559217760000},"page":"71-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still\u2019s Disease"],"prefix":"10.1007","volume":"58","author":[{"given":"Sheng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-297X","authenticated-orcid":false,"given":"Jianjun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,30]]},"reference":[{"issue":"2","key":"8747_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1136\/ard.30.2.121","volume":"30","author":"EG Bywaters","year":"1971","unstructured":"Bywaters EG (1971) Still\u2019s disease in the adult. Ann Rheum Dis 30(2):121\u2013133","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8747_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2188\/jea.7.221","volume":"7","author":"K Wakai","year":"1997","unstructured":"Wakai K, Ohta A, Tamakoshi A, Ohno Y, Kawamura T, Aoki R, Kojima M, Lin Y, Hashimoto S, Inaba Y, Minowa M, Aizawa S, Ichikawa Y, Miyasaka N (1997) Estimated prevalence and incidence of adult Still\u2019s disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 7(4):221\u2013225","journal-title":"J Epidemiol"},{"issue":"3","key":"8747_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3109\/14397595.2014.974881","volume":"25","author":"YF Asanuma","year":"2015","unstructured":"Asanuma YF, Mimura T, Tsuboi H, Noma H, Miyoshi F, Yamamoto K, Sumida T (2015) Nationwide epidemiological survey of 169 patients with adult Still\u2019s disease in Japan. Mod Rheumatol 25(3):393\u2013400. https:\/\/doi.org\/10.3109\/14397595.2014.974881","journal-title":"Mod Rheumatol"},{"issue":"1","key":"8747_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/03009740510026616","volume":"35","author":"KJ Evensen","year":"2006","unstructured":"Evensen KJ, Nossent HC (2006) Epidemiology and outcome of adult-onset Still\u2019s disease in Northern Norway. Scand J Rheumatol 35(1):48\u201351. https:\/\/doi.org\/10.1080\/03009740510026616","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"8747_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MD.0000000000000021","volume":"93","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I, Broussolle C, Seve P (2014) Adult-onset Still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 93(2):91\u201399. https:\/\/doi.org\/10.1097\/MD.0000000000000021","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"8747_CR6","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1742-1241.2007.01393.x","volume":"63","author":"Y Cagatay","year":"2009","unstructured":"Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, Ocal L, Aral O, Konice M (2009) Adult-onset Still\u2019s disease. Int J Clin Pract 63(7):1050\u20131055. https:\/\/doi.org\/10.1111\/j.1742-1241.2007.01393.x","journal-title":"Int J Clin Pract"},{"issue":"3","key":"8747_CR7","first-page":"424","volume":"19","author":"M Yamaguchi","year":"1992","unstructured":"Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still\u2019s disease. J Rheumatol 19(3):424\u2013430","journal-title":"J Rheumatol"},{"issue":"3","key":"8747_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1097\/00005792-200205000-00003","volume":"81","author":"B Fautrel","year":"2002","unstructured":"Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, Rozenberg S, Piette JC, Bourgeois P (2002) Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore) 81(3):194\u2013200","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"8747_CR9","first-page":"322","volume":"28","author":"B Fautrel","year":"2001","unstructured":"Fautrel B, Le Moel G, Saint-Marcoux B, Taupin P, Vignes S, Rozenberg S, Koeger AC, Meyer O, Guillevin L, Piette JC, Bourgeois P (2001) Diagnostic value of ferritin and glycosylated ferritin in adult onset Still\u2019s disease. J Rheumatol 28(2):322\u2013329","journal-title":"J Rheumatol"},{"issue":"4","key":"8747_CR10","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.semarthrit.2017.07.005","volume":"47","author":"D Lebrun","year":"2018","unstructured":"Lebrun D, Mestrallet S, Dehoux M, Golmard JL, Granger B, Georgin-Lavialle S, Arnaud L, Grateau G, Pouchot J, Fautrel B (2018) Validation of the Fautrel classification criteria for adult-onset Still\u2019s disease. Semin Arthritis Rheum 47(4):578\u2013585. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.07.005","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"8747_CR11","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/art.1780241203","volume":"24","author":"R Terkeltaub","year":"1981","unstructured":"Terkeltaub R, Esdaile JM, Decary F, Harth M, Lister J, Lapointe N (1981) HLA-Bw35 and prognosis in adult Still\u2019s disease. Arthritis Rheum 24(12):1469\u20131472","journal-title":"Arthritis Rheum"},{"issue":"3","key":"8747_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/art.1780290316","volume":"29","author":"JM Wouters","year":"1986","unstructured":"Wouters JM, Reekers P, van de Putte LB (1986) Adult-onset Still\u2019s disease. Disease course and HLA associations. Arthritis Rheum 29(3):415\u2013418","journal-title":"Arthritis Rheum"},{"issue":"12","key":"8747_CR13","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1093\/rheumatology\/40.12.1398","volume":"40","author":"T Fujii","year":"2001","unstructured":"Fujii T, Nojima T, Yasuoka H, Satoh S, Nakamura K, Kuwana M, Suwa A, Hirakata M, Mimori T (2001) Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 40(12):1398\u20131404","journal-title":"Rheumatology (Oxford)"},{"key":"8747_CR14","unstructured":"Joung CI, Lee HS, Lee SW, Kim CG, Song YH, Jun JB, Chung WT, Choe JY, Kim TG, Yoo DH (2003) Association between HLA-DR B1 and clinical features of adult onset Still\u2019s disease in Korea. Clin Exp Rheumatol 21(4):489\u2013492"},{"issue":"2","key":"8747_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/00005792-199103000-00004","volume":"70","author":"J Pouchot","year":"1991","unstructured":"Pouchot J, Sampalis JS, Beaudet F, Carette S, Decary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D et al (1991) Adult Still\u2019s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70(2):118\u2013136","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"8747_CR16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1172\/JCI2629","volume":"102","author":"D Fishman","year":"1998","unstructured":"Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102(7):1369\u20131376. https:\/\/doi.org\/10.1172\/JCI2629","journal-title":"J Clin Invest"},{"issue":"10","key":"8747_CR17","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.3899\/jrheum.090316","volume":"36","author":"DY Chen","year":"2009","unstructured":"Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2009) Functional association of interleukin 18 gene -607 (C\/A) promoter polymorphisms with disease course in Chinese patients with adult-onset Still\u2019s disease. J Rheumatol 36(10):2284\u20132289. https:\/\/doi.org\/10.3899\/jrheum.090316","journal-title":"J Rheumatol"},{"issue":"3","key":"8747_CR18","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1186\/ar4239","volume":"15","author":"FF Wang","year":"2013","unstructured":"Wang FF, Huang XF, Shen N, Leng L, Bucala R, Chen SL, Lu LJ (2013) A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still\u2019s disease. Arthritis Res Ther 15(3):R65. https:\/\/doi.org\/10.1186\/ar4239","journal-title":"Arthritis Res Ther"},{"issue":"49","key":"8747_CR19","doi-asserted-by":"publisher","first-page":"e13394","DOI":"10.1097\/MD.0000000000013394","volume":"97","author":"M Yashiro","year":"2018","unstructured":"Yashiro M, Furukawa H, Asano T, Sato S, Kobayashi H, Watanabe H, Suzuki E, Nakamura T, Koga T, Shimizu T, Umeda M, Nonaka F, Ueki Y, Eguchi K, Kawakami A, Migita K (2018) Serum amyloid A1 (SAA1) gene polymorphisms in Japanese patients with adult-onset Still\u2019s disease. Medicine (Baltimore) 97(49):e13394. https:\/\/doi.org\/10.1097\/MD.0000000000013394","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"8747_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/cei.12463","volume":"179","author":"F Nonaka","year":"2015","unstructured":"Nonaka F, Migita K, Jiuchi Y, Shimizu T, Umeda M, Iwamoto N, Fujikawa K, Izumi Y, Mizokami A, Nakashima M, Ueki Y, Yasunami M, Kawakami A, Eguchi K (2015) Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still\u2019s disease. Clin Exp Immunol 179(3):392\u2013397. https:\/\/doi.org\/10.1111\/cei.12463","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"8747_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","volume":"13","author":"M Gerfaud-Valentin","year":"2014","unstructured":"Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P (2014) Adult-onset Still\u2019s disease. Autoimmun Rev 13(7):708\u2013722. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.058","journal-title":"Autoimmun Rev"},{"issue":"10","key":"8747_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41584-018-0081-x","volume":"14","author":"E Feist","year":"2018","unstructured":"Feist E, Mitrovic S, Fautrel B (2018) Mechanisms, biomarkers and targets for adult-onset Still\u2019s disease. Nat Rev Rheumatol 14(10):603\u2013618. https:\/\/doi.org\/10.1038\/s41584-018-0081-x","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"8747_CR23","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3899\/jrheum.161354","volume":"44","author":"CW Hsieh","year":"2017","unstructured":"Hsieh CW, Chen YM, Lin CC, Tang KT, Chen HH, Hung WT, Lai KL, Chen DY (2017) Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset Still disease. J Rheumatol 44(8):1142\u20131150. https:\/\/doi.org\/10.3899\/jrheum.161354","journal-title":"J Rheumatol"},{"issue":"1","key":"8747_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13075-018-1800-z","volume":"21","author":"Q Hu","year":"2019","unstructured":"Hu Q, Shi H, Zeng T, Liu H, Su Y, Cheng X, Ye J, Yin Y, Liu M, Zheng H, Wu X, Chi H, Zhou Z, Jia J, Sun Y, Teng J, Yang C (2019) Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still\u2019s disease. Arthritis Res Ther 21(1):9. https:\/\/doi.org\/10.1186\/s13075-018-1800-z","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"8747_CR25","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3899\/jrheum.100247","volume":"37","author":"M Rau","year":"2010","unstructured":"Rau M, Schiller M, Krienke S, Heyder P, Lorenz H, Blank N (2010) Clinical manifestations but not cytokine profiles differentiate adult-onset Still\u2019s disease and sepsis. J Rheumatol 37(11):2369\u20132376. https:\/\/doi.org\/10.3899\/jrheum.100247","journal-title":"J Rheumatol"},{"issue":"11","key":"8747_CR26","first-page":"2422","volume":"30","author":"JH Choi","year":"2003","unstructured":"Choi JH, Suh CH, Lee YM, Suh YJ, Lee SK, Kim SS, Nahm DH, Park HS (2003) Serum cytokine profiles in patients with adult onset Still\u2019s disease. J Rheumatol 30(11):2422\u20132427","journal-title":"J Rheumatol"},{"issue":"11","key":"8747_CR27","first-page":"2189","volume":"31","author":"DY Chen","year":"2004","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY (2004) Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still\u2019s disease. J Rheumatol 31(11):2189\u20132198","journal-title":"J Rheumatol"},{"issue":"3","key":"8747_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jbspin.2017.05.011","volume":"85","author":"S Mitrovic","year":"2018","unstructured":"Mitrovic S, Fautrel B (2018) New markers for adult-onset Still\u2019s disease. Joint Bone Spine 85(3):285\u2013293. https:\/\/doi.org\/10.1016\/j.jbspin.2017.05.011","journal-title":"Joint Bone Spine"},{"issue":"11","key":"8747_CR29","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.autrev.2014.08.032","volume":"13","author":"AT Maria","year":"2014","unstructured":"Maria AT, Le Quellec A, Jorgensen C, Touitou I, Riviere S, Guilpain P (2014) Adult onset Still\u2019s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13(11):1149\u20131159. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.032","journal-title":"Autoimmun Rev"},{"issue":"1","key":"8747_CR30","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/ijms18010202","volume":"18","author":"Hyoun-Ah Kim","year":"2017","unstructured":"Kim HA, Choi B, Suh CH, Han MH, Jung JY, Sayeed HM, Kim YW, Sohn S (2017) Highly expression of CD11b and CD32 on peripheral blood mononuclear cells from patients with adult-onset Still\u2019s disease. Int J Mol Sci 18(1), 202. https:\/\/doi.org\/10.3390\/ijms18010202","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"8747_CR31","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3109\/03008200903461462","volume":"51","author":"DY Chen","year":"2010","unstructured":"Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL (2010) The associations of circulating CD4+CD25high regulatory T cells and TGF-beta with disease activity and clinical course in patients with adult-onset Still\u2019s disease. Connect Tissue Res 51(5):370\u2013377. https:\/\/doi.org\/10.3109\/03008200903461462","journal-title":"Connect Tissue Res"},{"issue":"10","key":"8747_CR32","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1136\/ard.2003.013680","volume":"63","author":"DY Chen","year":"2004","unstructured":"Chen DY, Lan JL, Lin FJ, Hsieh TY, Wen MC (2004) Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still\u2019s disease. Ann Rheum Dis 63(10):1300\u20131306. https:\/\/doi.org\/10.1136\/ard.2003.013680","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8747_CR33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A (2013) The interleukin-1 family: back to the future. Immunity 39(6):1003\u20131018. https:\/\/doi.org\/10.1016\/j.immuni.2013.11.010","journal-title":"Immunity"},{"issue":"6","key":"8747_CR34","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.immuni.2015.06.003","volume":"42","author":"IS Afonina","year":"2015","unstructured":"Afonina IS, Muller C, Martin SJ, Beyaert R (2015) Proteolytic processing of interleukin-1 family cytokines: variations on a common theme. Immunity 42(6):991\u20131004. https:\/\/doi.org\/10.1016\/j.immuni.2015.06.003","journal-title":"Immunity"},{"issue":"1","key":"8747_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/nrrheum.2016.166","volume":"12","author":"G Schett","year":"2016","unstructured":"Schett G, Dayer JM, Manger B (2016) Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol 12(1):14\u201324. https:\/\/doi.org\/10.1038\/nrrheum.2016.166","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"8747_CR36","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2008-03-146720","volume":"113","author":"MG Netea","year":"2009","unstructured":"Netea MG, Nold-Petry CA, Nold MF, Joosten LA, Opitz B, van der Meer JH, van de Veerdonk FL, Ferwerda G, Heinhuis B, Devesa I, Funk CJ, Mason RJ, Kullberg BJ, Rubartelli A, van der Meer JW, Dinarello CA (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood 113(10):2324\u20132335. https:\/\/doi.org\/10.1182\/blood-2008-03-146720","journal-title":"Blood"},{"key":"8747_CR37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/TCRM.S155488","volume":"14","author":"S Zhou","year":"2018","unstructured":"Zhou S, Qiao J, Bai J, Wu Y, Fang H (2018) Biological therapy of traditional therapy-resistant adult-onset Still\u2019s disease: an evidence-based review. Ther Clin Risk Manag 14:167\u2013171. https:\/\/doi.org\/10.2147\/TCRM.S155488","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"8747_CR38","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/art.21061","volume":"52","author":"AA Fitzgerald","year":"2005","unstructured":"Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA (2005) Rapid responses to anakinra in patients with refractory adult-onset Still\u2019s disease. Arthritis Rheum 52(6):1794\u20131803. https:\/\/doi.org\/10.1002\/art.21061","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8747_CR39","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/ard.2006.066381","volume":"66","author":"GD Kalliolias","year":"2007","unstructured":"Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN (2007) Anakinra treatment in patients with adult-onset Still\u2019s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66(6):842\u2013843. https:\/\/doi.org\/10.1136\/ard.2006.066381","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8747_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semarthrit.2007.04.002","volume":"37","author":"I Kotter","year":"2007","unstructured":"Kotter I, Wacker A, Koch S, Henes J, Richter C, Engel A, Gunaydin I, Kanz L (2007) Anakinra in patients with treatment-resistant adult-onset Still\u2019s disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37(3):189\u2013197. https:\/\/doi.org\/10.1016\/j.semarthrit.2007.04.002","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"8747_CR41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1136\/ard.2007.076034","volume":"67","author":"T Lequerre","year":"2008","unstructured":"Lequerre T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loet X, Sibilia J, Societe Francophone pour la Rhumatologie et les Maladies Inflammatoires en P, Club Rhumatismes et I (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67(3):302\u2013308. https:\/\/doi.org\/10.1136\/ard.2007.076034","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8747_CR42","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1136\/ard.2009.108068","volume":"69","author":"L Naumann","year":"2010","unstructured":"Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, Burmester GR (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still\u2019s disease. Ann Rheum Dis 69(2):466\u2013467. https:\/\/doi.org\/10.1136\/ard.2009.108068","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8747_CR43","doi-asserted-by":"publisher","first-page":"R91","DOI":"10.1186\/ar3366","volume":"13","author":"K Laskari","year":"2011","unstructured":"Laskari K, Tzioufas AG, Moutsopoulos HM (2011) Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still\u2019s disease: a case-series study. Arthritis Res Ther 13(3):R91. https:\/\/doi.org\/10.1186\/ar3366","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"8747_CR44","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstrom","year":"2012","unstructured":"Nordstrom D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A, Brun JG, Proven A, Ljung L, Kautiainen H, Pettersson T (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J Rheumatol 39(10):2008\u20132011. https:\/\/doi.org\/10.3899\/jrheum.111549","journal-title":"J Rheumatol"},{"issue":"5","key":"8747_CR45","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/acr.21901","volume":"65","author":"C Giampietro","year":"2013","unstructured":"Giampietro C, Ridene M, Lequerre T, Costedoat Chalumeau N, Amoura Z, Sellam J, Sibilia J, Bourgeois P, Fautrel B, Cri (2013) Anakinra in adult-onset Still\u2019s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res 65(5):822\u2013826. https:\/\/doi.org\/10.1002\/acr.21901","journal-title":"Arthritis Care Res"},{"issue":"4","key":"8747_CR46","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/03009742.2014.992949","volume":"44","author":"G Cavalli","year":"2015","unstructured":"Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Baldissera E, Dagna L (2015) Efficacy and safety of biological agents in adult-onset Still\u2019s disease. Scand J Rheumatol 44(4):309\u2013314. https:\/\/doi.org\/10.3109\/03009742.2014.992949","journal-title":"Scand J Rheumatol"},{"key":"8747_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-015-0228-7","volume":"10","author":"L Rossi-Semerano","year":"2015","unstructured":"Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, Touitou I, Kone-Paut I, MsGobo CRI (2015) Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 10:19. https:\/\/doi.org\/10.1186\/s13023-015-0228-7","journal-title":"Orphanet J Rare Dis"},{"issue":"39","key":"8747_CR48","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1097\/MD.0000000000001554","volume":"94","author":"F Ortiz-Sanjuan","year":"2015","unstructured":"Ortiz-Sanjuan F, Blanco R, Riancho-Zarrabeitia L, Castaneda S, Olive A, Riveros A, Velloso-Feijoo ML, Narvaez J, Jimenez-Moleon I, Maiz-Alonso O, Ordonez C, Bernal JA, Hernandez MV, Sifuentes-Giraldo WA, Gomez-Arango C, Galindez-Agirregoikoa E, Blanco-Madrigal J, Ortiz-Santamaria V, del Blanco-Barnusell J, De Dios JR, Moreno M, Fiter J, de los Riscos M, Carreira P, Rodriguez-Valls MJ, Gonzalez-Vela MC, Calvo-Rio V, Loricera J, Palmou-Fontana N, Pina T, Llorca J, Gonzalez-Gay MA (2015) Efficacy of Anakinra in refractory adult-onset Still\u2019s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554. https:\/\/doi.org\/10.1097\/MD.0000000000001554","journal-title":"Medicine (Baltimore)"},{"key":"8747_CR49","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3389\/fphar.2017.00369","volume":"8","author":"S Colafrancesco","year":"2017","unstructured":"Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Cantarini L, Cavallaro E, Cavalli G, Cerrito L, Cipriani P, Dagna L, Marchi G, Vita S, Emmi G, Ferraccioli G, Frassi M, Galeazzi M, Gerli R, Giacomelli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Ruscitti P, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Fabris F, Bindoli S, Punzi L, Galozzi P, Sfriso P (2017) Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still\u2019s disease: a multicentre retrospective observational study. Front Pharmacol 8:369. https:\/\/doi.org\/10.3389\/fphar.2017.00369","journal-title":"Front Pharmacol"},{"issue":"1","key":"8747_CR50","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13054-018-2012-2","volume":"22","author":"A Neel","year":"2018","unstructured":"Neel A, Wahbi A, Tessoulin B, Boileau J, Carpentier D, Decaux O, Fardet L, Geri G, Godmer P, Goujard C, Maisonneuve H, Mari A, Pouchot J, Ziza JM, Bretonniere C, Hamidou M (2018) Diagnostic and management of life-threatening adult-onset still disease: a French nationwide multicenter study and systematic literature review. Crit Care 22(1):88. https:\/\/doi.org\/10.1186\/s13054-018-2012-2","journal-title":"Crit Care"},{"issue":"4","key":"8747_CR51","first-page":"668","volume":"36","author":"E Feist","year":"2018","unstructured":"Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar CS, Speziale A (2018) Efficacy and safety of canakinumab in patients with Still\u2019s disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol 36(4):668\u2013675","journal-title":"Clin Exp Rheumatol"},{"key":"8747_CR52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.3389\/fphar.2019.00296","volume":"10","author":"A Vitale","year":"2019","unstructured":"Vitale A, Cavalli G, Colafrancesco S, Priori R, Valesini G, Argolini LM, Baldissera E, Bartoloni E, Cammelli D, Canestrari G, Sota J, Cavallaro E, Massaro MG, Ruscitti P, Cipriani P, De Marchi G, De Vita S, Emmi G, Ferraccioli G, Frassi M, Gerli R, Gremese E, Iannone F, Lapadula G, Lopalco G, Manna R, Mathieu A, Montecucco C, Mosca M, Piazza I, Piga M, Pontikaki I, Romano M, Rossi S, Rossini M, Silvestri E, Stagnaro C, Talarico R, Tincani A, Viapiana O, Vitiello G, Galozzi P, Sfriso P, Gaggiano C, Rigante D, Dagna L, Giacomelli R, Cantarini L (2019) Long-term retention rate of anakinra in adult onset Still\u2019s disease and predictive factors for treatment response. Front Pharmacol 10:296. https:\/\/doi.org\/10.3389\/fphar.2019.00296","journal-title":"Front Pharmacol"},{"issue":"12","key":"8747_CR53","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s40265-018-0956-9","volume":"78","author":"P Sfriso","year":"2018","unstructured":"Sfriso P, Bindoli S, Galozzi P (2018) Adult-onset Still\u2019s disease: molecular pathophysiology and therapeutic advances. Drugs 78(12):1187\u20131195. https:\/\/doi.org\/10.1007\/s40265-018-0956-9","journal-title":"Drugs"},{"issue":"2","key":"8747_CR54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.semarthrit.2012.03.004","volume":"42","author":"A Kontzias","year":"2012","unstructured":"Kontzias A, Efthimiou P (2012) The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still\u2019s disease. Semin Arthritis Rheum 42(2):201\u2013205. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.03.004","journal-title":"Semin Arthritis Rheum"},{"key":"8747_CR55","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fphar.2018.01074","volume":"9","author":"P Galozzi","year":"2018","unstructured":"Galozzi P, Baggio C, Bindoli S, Oliviero F, Sfriso P (2018) Development and role in therapy of canakinumab in adult-onset Still\u2019s disease. Front Pharmacol 9:1074. https:\/\/doi.org\/10.3389\/fphar.2018.01074","journal-title":"Front Pharmacol"},{"issue":"2","key":"8747_CR56","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.semarthrit.2017.06.006","volume":"47","author":"G Junge","year":"2017","unstructured":"Junge G, Mason J, Feist E (2017) Adult onset Still\u2019s disease-the evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum 47(2):295\u2013302. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.06.006","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"8747_CR57","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1136\/annrheumdis-2012-201409","volume":"71","author":"O Petryna","year":"2012","unstructured":"Petryna O, Cush JJ, Efthimiou P (2012) IL-1 trap rilonacept in refractory adult onset Still\u2019s disease. Ann Rheum Dis 71(12):2056\u20132057. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201409","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8747_CR58","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12616","volume":"281","author":"G Kaplanski","year":"2018","unstructured":"Kaplanski G (2018) Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev 281(1):138\u2013153. https:\/\/doi.org\/10.1111\/imr.12616","journal-title":"Immunol Rev"},{"issue":"12","key":"8747_CR59","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/rheumatology\/kew300","volume":"55","author":"C Girard","year":"2016","unstructured":"Girard C, Rech J, Brown M, Allali D, Roux-Lombard P, Spertini F, Schiffrin EJ, Schett G, Manger B, Bas S, Del Val G, Gabay C (2016) Elevated serum levels of free interleukin-18 in adult-onset Still\u2019s disease. Rheumatology (Oxford) 55(12):2237\u20132247. https:\/\/doi.org\/10.1093\/rheumatology\/kew300","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"8747_CR60","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3899\/jrheum.090662","volume":"37","author":"J Maruyama","year":"2010","unstructured":"Maruyama J, Inokuma S (2010) Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol 37(5):967\u2013973. https:\/\/doi.org\/10.3899\/jrheum.090662","journal-title":"J Rheumatol"},{"issue":"6","key":"8747_CR61","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kotter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis 77(6):840\u2013847. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212608","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8747_CR62","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1136\/annrheumdis-2018-214496","volume":"79","author":"Uta Kiltz","year":"2018","unstructured":"Kiltz U, Kiefer D, Braun J, Schiffrin EJ, Girard-Guyonvarc'h C, Gabay C (2018) Prolonged treatment with Tadekinig alfa in adult-onset Still\u2019s disease. Ann Rheum Dis annrheumdis-2018-214496. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214496","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"8747_CR63","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1042\/bj2650621","volume":"265","author":"PC Heinrich","year":"1990","unstructured":"Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621\u2013636. https:\/\/doi.org\/10.1042\/bj2650621","journal-title":"Biochem J"},{"issue":"6","key":"8747_CR64","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nsmb941","volume":"12","author":"G Skiniotis","year":"2005","unstructured":"Skiniotis G, Boulanger MJ, Garcia KC, Walz T (2005) Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol 12(6):545\u2013551. https:\/\/doi.org\/10.1038\/nsmb941","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"8747_CR65","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.183.4.1399","volume":"183","author":"M Peters","year":"1996","unstructured":"Peters M, Jacobs S, Ehlers M, Vollmer P, Mullberg J, Wolf E, Brem G, Meyer zum Buschenfelde KH, Rose-John S (1996) The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med 183(4):1399\u20131406. https:\/\/doi.org\/10.1084\/jem.183.4.1399","journal-title":"J Exp Med"},{"issue":"5","key":"8747_CR66","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/ni.3153","volume":"16","author":"CA Hunter","year":"2015","unstructured":"Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16(5):448\u2013457. https:\/\/doi.org\/10.1038\/ni.3153","journal-title":"Nat Immunol"},{"issue":"4","key":"8747_CR67","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M (2012) IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 122(4):143\u2013159. https:\/\/doi.org\/10.1042\/CS20110340","journal-title":"Clin Sci (Lond)"},{"key":"8747_CR68","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","volume":"169","author":"N Inoue","year":"2016","unstructured":"Inoue N, Shimizu M, Tsunoda S, Kawano M, Matsumura M, Yachie A (2016) Cytokine profile in adult-onset Still\u2019s disease: comparison with systemic juvenile idiopathic arthritis. Clin Immunol 169:8\u201313. https:\/\/doi.org\/10.1016\/j.clim.2016.05.010","journal-title":"Clin Immunol"},{"issue":"5","key":"8747_CR69","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14397595.2017.1416924","volume":"28","author":"Y Ma","year":"2018","unstructured":"Ma Y, Wu M, Zhang X, Xia Q, Yang J, Xu S, Pan F (2018) Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still\u2019s disease: a meta-analysis. Mod Rheumatol 28(5):849\u2013857. https:\/\/doi.org\/10.1080\/14397595.2017.1416924","journal-title":"Mod Rheumatol"},{"issue":"1","key":"8747_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10165-008-0116-2","volume":"19","author":"H Nakahara","year":"2009","unstructured":"Nakahara H, Mima T, Yoshio-Hoshino N, Matsushita M, Hashimoto J, Nishimoto N (2009) A case report of a patient with refractory adult-onset Still\u2019s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 19(1):69\u201372. https:\/\/doi.org\/10.1007\/s10165-008-0116-2","journal-title":"Mod Rheumatol"},{"issue":"1","key":"8747_CR71","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/acr.20319","volume":"63","author":"X Puechal","year":"2011","unstructured":"Puechal X, DeBandt M, Berthelot JM, Breban M, Dubost JJ, Fain O, Kahn JE, Lequen L, Longy-Boursier M, Perdriger A, Schaeverbeke T, Toussirot E, Sibilia J, Club Rhumatismes Et I (2011) Tocilizumab in refractory adult Still\u2019s disease. Arthritis Care Res 63(1):155\u2013159. https:\/\/doi.org\/10.1002\/acr.20319","journal-title":"Arthritis Care Res"},{"issue":"5","key":"8747_CR72","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s10165-011-0569-6","volume":"22","author":"R Suematsu","year":"2012","unstructured":"Suematsu R, Ohta A, Matsuura E, Takahashi H, Fujii T, Horiuchi T, Minota S, Ishigatsubo Y, Ota T, Takei S, Soejima S, Inoue H, Koarada S, Tada Y, Nagasawa K (2012) Therapeutic response of patients with adult Still\u2019s disease to biologic agents: multicenter results in Japan. Mod Rheumatol 22(5):712\u2013719. https:\/\/doi.org\/10.1007\/s10165-011-0569-6","journal-title":"Mod Rheumatol"},{"issue":"1","key":"8747_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10067-013-2381-5","volume":"33","author":"P Cipriani","year":"2014","unstructured":"Cipriani P, Ruscitti P, Carubbi F, Pantano I, Liakouli V, Berardicurti O, Giacomelli R (2014) Tocilizumab for the treatment of adult-onset Still\u2019s disease: results from a case series. Clin Rheumatol 33(1):49\u201355. https:\/\/doi.org\/10.1007\/s10067-013-2381-5","journal-title":"Clin Rheumatol"},{"issue":"2","key":"8747_CR74","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3899\/jrheum.130881","volume":"41","author":"O Elkayam","year":"2014","unstructured":"Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, Ablin J, Abu-Shakra M, Savargyl-Maman H, Padova H, Caspi D, Rosner I (2014) Tocilizumab in adult-onset Still\u2019s disease: the Israeli experience. J Rheumatol 41(2):244\u2013247. https:\/\/doi.org\/10.3899\/jrheum.130881","journal-title":"J Rheumatol"},{"issue":"6","key":"8747_CR75","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1002\/art.38398","volume":"66","author":"F Ortiz-Sanjuan","year":"2014","unstructured":"Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, Narvaez J, Rubio Romero E, Olive A, Castaneda S, Gallego Flores A, Hernandez MV, Mata C, Ros Vilamajo I, Sifuentes Giraldo WA, Caracuel MA, Freire M, Gomez Arango C, Llobet J, Manrique Arija S, Marras C, Moll-Tuduri C, Plasencia-Rodriguez C, Rosello R, Urruticoechea A, Velloso-Feijoo ML, Del Blanco J, Gonzalez-Vela MC, Rueda-Gotor J, Pina T, Loricera J, Gonzalez-Gay MA (2014) Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still\u2019s disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheum 66(6):1659\u20131665. https:\/\/doi.org\/10.1002\/art.38398","journal-title":"Arthritis Rheum"},{"issue":"2","key":"8747_CR76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/14397595.2014.899178","volume":"26","author":"E Bannai","year":"2016","unstructured":"Bannai E, Yamashita H, Kaneko S, Ueda Y, Ozaki T, Tsuchiya H, Takahashi Y, Kaneko H, Kano T, Mimori A (2016) Successful tocilizumab therapy in seven patients with refractory adult-onset Still\u2019s disease. Mod Rheumatol 26(2):297\u2013301. https:\/\/doi.org\/10.3109\/14397595.2014.899178","journal-title":"Mod Rheumatol"},{"issue":"3","key":"8747_CR77","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/14397595.2014.973659","volume":"25","author":"N Nishina","year":"2015","unstructured":"Nishina N, Kaneko Y, Kameda H, Takeuchi T (2015) The effect of tocilizumab on preventing relapses in adult-onset Still\u2019s disease: a retrospective, single-center study. Mod Rheumatol 25(3):401\u2013404. https:\/\/doi.org\/10.3109\/14397595.2014.973659","journal-title":"Mod Rheumatol"},{"issue":"6 Suppl 102","key":"8747_CR78","first-page":"S64","volume":"34","author":"ST Song","year":"2016","unstructured":"Song ST, Kim JJ, Lee S, Kim HA, Lee EY, Shin KC, Lee JH, Lee KH, Choi ST, Cha HS, Yoo DH (2016) Efficacy of tocilizumab therapy in Korean patients with adult-onset Still\u2019s disease: a multicentre retrospective study of 22 cases. Clin Exp Rheumatol 34(6 Suppl 102):S64\u2013S71","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"8747_CR79","doi-asserted-by":"publisher","first-page":"13477","DOI":"10.1038\/s41598-017-13639-y","volume":"7","author":"T Li","year":"2017","unstructured":"Li T, Gu L, Wang X, Guo L, Shi H, Yang C, Chen S (2017) A pilot study on tocilizumab for treating refractory adult-onset Still\u2019s disease. Sci Rep 7(1):13477. https:\/\/doi.org\/10.1038\/s41598-017-13639-y","journal-title":"Sci Rep"},{"issue":"12","key":"8747_CR80","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1136\/annrheumdis-2018-213920","volume":"77","author":"Y Kaneko","year":"2018","unstructured":"Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H, Tanaka Y, Abe T, Takeuchi T (2018) Tocilizumab in patients with adult-onset Still\u2019s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77(12):1720\u20131729. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213920","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8747_CR81","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13075-019-1838-6","volume":"21","author":"F Vercruysse","year":"2019","unstructured":"Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, Delbrel X, Fautrel B, Richez C, Schaeverbeke T, Truchetet ME (2019) Adult-onset Still\u2019s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21(1):53. https:\/\/doi.org\/10.1186\/s13075-019-1838-6","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"8747_CR82","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/nrd3030","volume":"9","author":"D Faustman","year":"2010","unstructured":"Faustman D, Davis M (2010) TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov 9(6):482\u2013493. https:\/\/doi.org\/10.1038\/nrd3030","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"8747_CR83","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nri1184","volume":"3","author":"BB Aggarwal","year":"2003","unstructured":"Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745\u2013756. https:\/\/doi.org\/10.1038\/nri1184","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 3","key":"8747_CR84","first-page":"iii55","volume":"60","author":"HG Kraetsch","year":"2001","unstructured":"Kraetsch HG, Antoni C, Kalden JR, Manger B (2001) Successful treatment of a small cohort of patients with adult onset of Still\u2019s disease with infliximab: first experiences. Ann Rheum Dis 60(Suppl 3):iii55\u2013iii57","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8747_CR85","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/ard.2004.024026","volume":"64","author":"B Fautrel","year":"2005","unstructured":"Fautrel B, Sibilia J, Mariette X, Combe B, Club Rhumatismes et I (2005) Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis 64(2):262\u2013266. https:\/\/doi.org\/10.1136\/ard.2004.024026","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"8747_CR86","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/art.10231","volume":"46","author":"ME Husni","year":"2002","unstructured":"Husni ME, Maier AL, Mease PJ, Overman SS, Fraser P, Gravallese EM, Weinblatt ME (2002) Etanercept in the treatment of adult patients with Still\u2019s disease. Arthritis Rheum 46(5):1171\u20131176. https:\/\/doi.org\/10.1002\/art.10231","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-019-08747-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-019-08747-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-019-08747-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:20:16Z","timestamp":1659093616000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-019-08747-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,30]]},"references-count":86,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["8747"],"URL":"https:\/\/doi.org\/10.1007\/s12016-019-08747-8","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,30]]},"assertion":[{"value":"30 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}